X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Scrutinises 2 Cancer Permits Sans Voluntary Withdrawals

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Scrutinises 2 Cancer Permits Sans Voluntary Withdrawals

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

Content Team by Content Team
18th July 2022
in Market Moves, Press Statements
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.

Grünenthal has agreed to acquire testosterone treatment NebidoTM and its associated brands from Bayer AG, for up to €500 million.

The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries. Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States.

Nebido is typically administered by a physician every 10-14 weeks for treatment of male hypogonadism or testosterone deficiency,

It can also be used to treat clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction.

“One in six men over 50 live with the symptoms of testosterone deficiency. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need,” commented Gabriel Baertschi, CEO of Grünenthal.

The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities.

Grünenthal has invested over €2 billion in successful M&A transactions over the last several years. The latest deal to buy testosterone treatment Nebido from Bayer will expand its existing portfolio of medicines.

In 2018, Grünenthal acquired the European rights to Nexium™ as well as the global rights to Vimovo™ (ex-US and Japan) from AstraZeneca. Nexium helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. Vimovo is a modified-release fixed-dose combination tablet of naproxen, a pain-relieving NSAID and esomeprazole, the active ingredient in Nexium, for the treatment of various inflammatory diseases.

Grünenthal also acquired the European rights (excluding Spain and the UK) to statin CRESTOR™  from AstraZeneca, the rights to Qutenza™ (capsaicin 8% patch) from Astellas Pharma Europe, and has the global rights (excluding Japan) to AstraZeneca’s migraine therapy Zomig™.

In 2021, Grünenthal acquired Mestex AG, a Swiss biotech, and its clinical phase medicine resiniferatoxin (MTX-071) for the intra-articular treatment of pain associated with osteoarthritis of the knee.

Previous Post

The US Has Prolonged The COVID-19 Public Health Emergency

Next Post

Serum Institute Wins USFDA Nod To Export Novavax COVID Jab

Related Posts

Shimadzu's Nexera XS Inert Chromatography System Enhances Biopharma Analysis
IPR Data Management

Shimadzu’s Nexera XS Inert Chromatography System Enhances Biopharma Analysis

28th July 2022
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Drug Development

Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

27th July 2022
Merck and Orion Announce Global Collaboration for Oncology Drug
Drug Development

Merck and Orion Announce Global Collaboration for Oncology Drug

26th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement
Packaging & Logistic

DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement

13th July 2022
Next Post
Serum Institute Wins USFDA Nod To Export Novavax COVID Jab

Serum Institute Wins USFDA Nod To Export Novavax COVID Jab

Latest News

NHS Lays Long COVID Action Plan For Many With Chronic Signs
Facilities & Operation

NHS Lays Long COVID Action Plan For Many With Chronic Signs

30th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Drug Development

Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

30th July 2022
GSK Unveils Its Transformation Through New Branding And Logo
News

GSK To Aid 12 European Countries Prepare For Future Pandemic

29th July 2022
Shimadzu's Nexera XS Inert Chromatography System Enhances Biopharma Analysis
IPR Data Management

Shimadzu’s Nexera XS Inert Chromatography System Enhances Biopharma Analysis

28th July 2022
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Drug Development

Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

27th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In